Wegovy-maker Novo Nordisk cuts outlook again as obesity drug sales slow – Reuters
- Wegovy-maker Novo Nordisk cuts outlook again as obesity drug sales slow Reuters
- Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount CNBC
- Should You Buy Novo Nordisk Stock Before the Huge Investor Update? Nasdaq
- Novo Nordisk CEO faces baptism of fire amid board shakeup, Pfizer fight Reuters
- Novo Nordisk’s sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues Yahoo Finance